More Than 10 Years' Continuous Oral Treatment with Specific Immunoglobulin Y for the Prevention of<i>Pseudomonas aeruginosa</i>Infections: A Case Report

Nilsson, Elin; Kollberg, H; Johannesson, Marie; Wejåker, Per-Erik; Carlander, David; Larsson, Anders

doi:10.1089/jmf.2006.214

Cited by 48 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to these advantages, a chicken can provide more than 40 g IgY per year (15). Thus far, numerous studies on IgY used for immunotherapy in clinical and experimental treatments have been reported (16)(17)(18)(19)(20). However, poly-clonal antibodies, including IgY, are prone to cross-reactions and are of inconsistent quality.…”

mentioning

confidence: 99%

Antibodies against Venom of the Snake Deinagkistrodon acutus

Lee

Liang

et al. 2016

Appl Environ Microbiol

View full text Add to dashboard Cite

h Snake venom protein from Deinagkistrodon acutus (DA protein), one of the major venomous species in Taiwan, causes hemorrhagic symptoms that can lead to death. Although horse-derived antivenin is a major treatment, relatively strong and detrimental side effects are seen occasionally. In our study, yolk immunoglobulin (IgY) was purified from eggs, and DA protein was recognized using Western blotting and an enzyme-linked immunosorbent assay (ELISA), similar to therapeutic horse antivenin. The ELISA also indicated that specific IgY antibodies were elicited after the fifth booster, plateaued, and lasted for at least 3 months. To generate monoclonal single-chain variable fragment (scFv) antibodies, we used phage display technology to construct two libraries with short or long linkers, containing 6.24 ؋ 10 8 and 5.28 ؋ 10 8 transformants, respectively. After four rounds of biopanning, the eluted phage titer increased, and the phage-based ELISA indicated that the specific clones were enriched. Nucleotide sequences of 30 individual clones expressing scFv were analyzed and classified into four groups that all specifically recognized the DA venom protein. Furthermore, based on mass spectrometry, the scFv-bound protein was deduced to be snake venom metalloproteinase proteins. Most importantly, both IgY and mixed scFv inhibited the lethal effect in mice injected with the minimum lethal dosage of the DA protein. We suggest that together, these antibodies could be applied to the development of diagnostic agents or treatments for snakebite envenomation in the future.

show abstract

mentioning

confidence: 99%

Antibodies against Venom of the Snake Deinagkistrodon acutus

Lee

Liang

et al. 2016

Appl Environ Microbiol

View full text Add to dashboard Cite

show abstract

“…Furthermore, to evaluate the antibacterial performance of the PCMSs-IgY, S. mutans, which generally causes severe tooth demineralization and cavity formation, was chosen as the representative bacterial model in this study [33,34]. The inhibitory effect of three samples (PCMSs-IgY, pure PCMSs, and free IgY; the IgY concentration was fixed at 4.5 mg mL −1 for IgY-containing samples) were examined against S. mutans, based on the colony counting approach (Fig.…”

Section: Antibacterial Performance Of Pcmss-igymentioning

confidence: 99%

Symmetry-breaking assembled porous calcite microspheres and their multiple dental applications

Yan

et al. 2017

Sci. China Mater.

View full text Add to dashboard Cite

Biomedical applications of porous calcium carbonate (CaCO3) microspheres have been mainly restricted by their aqueous instability and low remineralization rate. To overcome these obstacles, a novel symmetry-breaking assembled porous calcite microsphere (PCMS) was constructed in an ethanol/water mixed system using a two-step vapor-diffusion/aging crystallization strategy. In contrast to the conventional additive-induced crystallization method, the present strategy was performed under mild conditions and was free from any foreign additives, thus avoiding the potential contamination of the final product. Meanwhile, the prepared PCMSs were characterized by their highly uniform spherical morphology and large open pores, which are favorable for large protein delivery. An antimicrobial study of immunoglobulin Y (IgY)-loaded PCMSs revealed excellent antimicrobial activity against Streptococcus mutans. More importantly, they showed surprisingly rapid transformation to bone minerals in physiological medium. Evaluation of the in vitro efficacy of PCMSs in dentinal tubule occlusion demonstrated their powerful potential to serve as a catalyst in the repair of dental hard tissue. Therefore, the developed PCMSs show great promise as multifunctional biomaterials for dental treatment applications.

show abstract

“…Oral administration of IgY antibodies has been tested for many years with promising results [80] to different pathogens as human rotavirus [81]; dental plaque formation by Streptococcus mutans [82,83]; enteropathogenic E. coli [84]; Helicobacter pylori [85,86]; Cryptosporidium parvum [87,88]; canine parvovirus [89]; Porphyromonas gingivalis [90]; Pseudomonas aeruginosa [91]; shrimp's white spot syndrome virus [92]; Eimeria acervulina [93]; E. tenella and E. maxima [94,95]; H5N1 e H1N1 in mice [96]; Vibrio cholerae [97]; rotavirus and norovirus [98]; Campylobacter jejuni [99][100][101]; and botulinum neurotoxins [102]. Immunotherapy as a passive immunization method to neutralize venom using purified IgY proved to be efficient for therapy protocol [103][104][105][106][107].…”

Section: Using Igy For Passive Immunizationmentioning

confidence: 99%

IgY-Technology Applied to Studies of Toxoplasma gondii Infection

Júnior¹,

Santos²,

Bassi³

et al. 2017

Toxoplasmosis

View full text Add to dashboard Cite

In this chapter, we describe relevant aspects of immunoglobulin Y (IgY) technology for Toxoplasma gondii applications, including comparison of avian IgY antibody with mammalian IgG antibody, egg yolk IgY production and isolation procedures, important applications for IgY antibody, and state of the art and perspectives for IgY-technology in T. gondii studies. T. gondii is a worldwide public health problem. IgY-technology provides an alternative antibody (IgY) to mammalian Immunoglobulin G (IgG) antibody. IgY-technology involves the chicken immunization, yolk IgY isolation, antibody characterization, and purified IgY application to several kinds of methods. Immunized chicken transfers a specific IgY from blood to egg yolk. Phylogenetic distance between chickens and mammals influences the generation of antibody repertoires recognizing an antigen profile. IgY is not bound to rheumatoid factor or mammalian complement protein and thus avoids the false-positive results. Yolk IgY isolation is carried out by simple procedures that are accessible for any laboratory and, also, for IgY isolation at large-scale production. IgY-technology provides antibodies for proteomic studies, diagnostic assays, and immunotherapy. Although IgY-technology is promising, there is a reduced number of investigations with IgY and T. gondii. Future perspectives involve the use of IgY-technology for the screening of new T. gondii antigens for diagnostics, therapy, or vaccine, development of innovative techniques for toxoplasmosis diagnostics and may be an immunotherapy for toxoplasmosis.

show abstract

More Than 10 Years' Continuous Oral Treatment with Specific Immunoglobulin Y for the Prevention ofPseudomonas aeruginosaInfections: A Case Report

Cited by 48 publications

References 29 publications

Antibodies against Venom of the Snake Deinagkistrodon acutus

Antibodies against Venom of the Snake Deinagkistrodon acutus

Symmetry-breaking assembled porous calcite microspheres and their multiple dental applications

IgY-Technology Applied to Studies of Toxoplasma gondii Infection

Contact Info

Product

Resources

About